F2G
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Suite 18.04 Arrive Blue Blue Tower, Salf...Phone Number
+44 1617851270Website
www.f2g.comRevenue
$15.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About F2G
F2G is a biopharmaceutical company dedicated to developing novel therapies targeting rare, life-threatening fungal infections. The company emphasizes patient-first approaches and innovative science to create effective antifungal treatments. With a tenacious team, F2G aims to provide more therapeutic options for patients facing challenges from resistant fungal pathogens. Their efforts contribute towards the advancement of life-saving treatments for specific patient populations.Explore more
F2G Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is F2G your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once F2G has new funding data
F2G, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at F2G
Product Launch: Get notified when F2G launches new products
Check if F2G has recently received funding, and reach out quickly before it becomes old news!
Check out if F2G is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on F2G recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if F2G had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined F2G as Masked Content
Find 2 more new buyers
Compare Similar Companies to F2G
Compare insights from companies similar to F2G, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
F2G is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
F2G is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about F2G.
F2G financials insights
Gather financial insights about F2G, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2002
Series A
$6.1M
2008
Private Equity
$9.2M
Other Financing Round
$11.8M
2012
Private Equity
$30M
2016
Series C
$60M
2020
Series D
$60.8M
2022
Unspecified
$70M
2024
Other Financing Round
$100M
F2G Tech Stack
A closer look at the technologies used by F2G
See more technologies
Most Recent Scoops
Funding
Funding
Award
Award
Open Position
Funding
F2G News & Media
Antifungal drugs, haptics and carbon accounting in this week's MaddyMoney - Maddyness
Every week, Maddyness brings you the latest investment news from the UK startup ecosystem. Here's a recap of this week's investments.F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the US
MANCHESTER, United Kingdom, Sept. 12, 2024 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a high unmet medical need, today announced a $100 million financing round. The financing is being led by new investor AMR Action Fund and co-led by ICG, with strong participation from existing investors Novo Holdings, Advent Life Sciences, Sofinnova Partners, Forbion, BlF2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for The Treatment of Invasive Fungal Infections; Plans Resubmission With Additional Data and Analyses
MANCHESTER, United Kingdom, June 19, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for olorofim, an investigational antifungal, for the treatment of invasive fungal infections in patients who have limited or no treatment options.F2G Wins Investment Deal of the Year Bionow 2022 Award
MANCHESTER, United Kingdom, March 17, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced the company has been awarded a prestigious Bionow award in recognition of its contributions to the North England biotech industry and progress towards developing a new class of antifungals for treatment of rare fungal infections. F2G was awarded Investment Deal of the Year at the Bionow awards ceremony which was held at the iconic Concorde Conference Centre in Manchester, United Kingdom, on
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding F2G
Sign Up For FreeTo access detailed company insights
F2G is a biopharmaceutical company dedicated to developing novel therapies targeting rare, life-threatening fungal infections. The company emphasizes patient-first approaches and innovative science to create effective antifungal treatments. With a tenacious team, F2G aims to provide more therapeutic options for patients facing challenges from resis... Read More
